Elcatonin

Elcatonin is a synthetic analog of eel calcitonin, structurally modified to replace the disulfide bridge of natural calcitonin with a more stable aminosuberic acid linkage. This modification enhances chemical stability while preserving the peptide's biological activity as a calcitonin receptor agonist. Elcatonin has been used clinically since the 1980s, primarily in Japan and some other Asian countries, for the treatment of osteoporosis and associated bone pain.

Like other calcitonin preparations, elcatonin inhibits osteoclast-mediated bone resorption by binding to calcitonin receptors on osteoclast cell membranes, leading to reduced osteoclast motility and activity. This results in decreased bone turnover and a modest increase in bone mineral density over time. The drug also possesses analgesic properties that are particularly valued in the management of pain associated with osteoporotic vertebral fractures, a property shared with salmon calcitonin.

The analgesic mechanism of elcatonin involves both peripheral and central components. Peripherally, the reduction in bone turnover decreases the release of pain-mediating substances from bone. Centrally, calcitonin receptors in the CNS modulate descending pain inhibitory pathways, potentially involving serotonergic and endorphin-mediated mechanisms. Clinical studies in Japan have demonstrated significant pain relief in patients with osteoporotic back pain.

Elcatonin is typically administered as an intramuscular injection, which distinguishes it from salmon calcitonin nasal spray that is more commonly used in Western countries. The standard regimen involves injection once weekly, which is more convenient than the daily dosing required for some other calcitonin preparations. However, like all calcitonin preparations, elcatonin has been largely supplanted in first-line osteoporosis management by more effective agents.